

September 27, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer

TOKYO, Japan, September 27, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that its U.S. licensor for rigosertib, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, "Onconova"), provided preliminary safety and efficacy data on September 22, 2021 (EST) on the investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor, nivolumab, in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC). The data, which were presented at the 3rd Annual RAS Targeted Drug Development Summit on September 22, 2021, support the potential anti-cancer activity of the rigosertib-nivolumab combination in this indication and show that the doublet has been well tolerated to-date.

For Onconova's full press release, please visit Onconova's website:
<https://investor.onconova.com/press-releases>

About Rigosertib

Rigosertib is a small molecule multi-kinase inhibitor that inhibits RAS associated cellular signaling in cancer cells necessary for their survival and proliferation. Rigosertib has also been reported to have immunomodulatory activity by influencing the host immune system to target cancer cells. SymBio obtained the development and commercialization licensing rights for Rigosertib from Onconova in July, 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer. Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. For more information, please visit <https://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May, 2016 the Company incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.